TABLE 4.
Ongoing combination trials of DDR inhibitors with immunotherapy
| DDR | Conditions | Interventions | Phase | Clinical trial* |
|---|---|---|---|---|
| PARP | ||||
| Endometrial neoplasms | Olaparib + durvaluma | II | NCT03951415 | |
| Solid tumor | Rucaparib + atezolizumab | II | NCT04276376 | |
| Biliary tract cancer | Rucaparib + nivolumab | II | NCT03639935 | |
| Lung small cell carcinoma, neuroendocrine carcinoma | Niraparib + dostarlimab | II | NCT04701307 | |
| Cervical cancer | Olaparib + pembrolizumab | II | NCT04483544 | |
| Breast cancer | Olaparib + pembrolizumab | II | NCT03025035 | |
| Ovarian, breast, gastric cancer, SCLC | Olaparib + durvalumab | I/II | NCT02734004 | |
| Ovarian neoplasms | Niraparib + TSR‐042 | II | NCT03574779 | |
| Ovarian, fallopian tube, peritoneal cancer | Olaparib + tremelimumab | I/II | NCT02571725 | |
| Metastatic pancreatic adenocarcinoma | Olaparib + pembrolizumab | II | NCT04548752 | |
| Advanced malignant solid neoplasm | Niraparib + atezolizumab | I | NCT03830918 | |
| Advanced malignant solid neoplasm | Olaparib + durvalumab/copanlisib | I | NCT03842228 | |
| Metastatic breast carcinoma | Olaparib + atezolizumab | II | NCT02849496 | |
| LSCL | Olaparib + durvalumab | I | NCT04728230 | |
| Platinum‐sensitive ovarian cancer | OSE2101 + pembrolizumab | II | NCT04713514 | |
| Advanced malignant solid neoplasm | Talazoparib + paclitaxel | I | NCT02317874 | |
| Colorectal, breast neoplasms | Olaparib + durvalumab | I/II | NCT02484404 | |
| Prostate carcinoma | Olaparib + durvalumab | II | NCT04336943 | |
| Breast cancer | Niraparib + TSR‐042 (dostarlimab) | I | NCT04673448 | |
| Triple negative breast cancer | Olaparib + durvalumab | II | NCT03167619 | |
| Extensive SLSC | Talazoparib + atezolizumab | II | NCT04334941 | |
| Fallopian tube mucinous adenocarcinoma | Olaparib + cediranib + durvalumab | II | NCT04739800 | |
| Metastatic triple negative breast cancer | Olaparib + durvalumab | II | NCT03801369 | |
| Breast, ovarian cancer | Niraparib + pembrolizumab | I/II | NCT02657889 | |
| BRCAm ovarian, fallopian tube or primary peritoneal cancer | Olaparib + durvalumab/tremelimumab | II | NCT02953457 | |
| Ovarian, fallopian tube, or primary peritoneal cancer | Rucaparib + nivolumab | III | NCT03522246 | |
| Ovarian carcinosarcoma | Niraparib + TSR‐042 (dostarlimab) | II/III | NCT03651206 | |
| Pancreatic adenocarcinoma | Niraparib + nivolumab/ipilimumab | I/II | NCT03404960 | |
| Endometrial cancer | Olaparib + durvalumab | II | NCT03660826 | |
| Metastatic solid tumors | Talazoparib + avelumab | II | NCT03330405 | |
| BRCA1/2 and PALB2 mutated metastatic pancreatic cancer | Niraparib + dostarlimab | II | NCT04493060 | |
| Advanced solid neoplasm | Veliparib + nivolumab | I | NCT03061188 | |
| Metastatic melanoma with HR mutation | Olaparib + pembrolizumab | II | NCT04633902 | |
| ATM | ||||
| Advanced solid tumors | Drug: BAY1895344 + pembrolizumab | I | NCT04095273 | |
| ATR | ||||
| Advanced solid tumors | BAY1895344 + pembrolizumab | I | NCT04095273 | |
*
Data from https://clinicaltrials.gov.